4.4 Article

LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127

Journal

IMMUNOLOGIC RESEARCH
Volume 65, Issue 3, Pages 630-638

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12026-016-8881-z

Keywords

Dendritic cell; EAE; Immune tolerance; CD4(+) T cell

Categories

Funding

  1. NIAID NIH HHS [R01 AI106026, R01 AI124386] Funding Source: Medline
  2. NINDS NIH HHS [R01 NS075260] Funding Source: Medline

Ask authors/readers for more resources

Intravenous transfer of LPS-treated bone marrow-derived dendritic cells blocks development of autoimmunity induced by CD4(+) T cells in vivo. However, cellular mechanisms of dendritic cell-mediated immune tolerance have not yet been fully elucidated. Here, we report that there are two new subpopulations of CD4(+)CD25(+)FoxP3(+)GITR(+) regulatory T cells (CD127(+)3G11(+) and CD127(+)3G11(-) cells). LPS-treated dendritic cells facilitate development of CD4(+)CD127(+)3G11(-) regulatory T cells but inhibit that of CD4(+)CD127(+)3G11(+) regulatory T cells. LPS-induced tolerogenic dendritic cells may cause immune tolerance through modulating balance of different subsets of CD4(+) regulatory T cells mediated by CD127 and 3G11. Our results imply a new potential cellular mechanism of dendritic cell-mediated immune tolerance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available